Anti-ATP13A2 (C-terminal region) antibody produced in rabbit
SIGMA/A3361 - ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Synonym: Anti-ATPase type 13A2; Anti-PARK9
Product Type: Chemical
Enhanced Validation-By Recombinant Expression Antibody recognition: Anti-ATP13A2 (C-terminal region) antibody produced in Rabbit (Cat. No. A3361) is confirmed by western blot in the cell sample that has been altered to overexpress the target protein-HEK-293T over expressing ATP13A2 (Lane 1) while no staining is detected in the wild type sample-HEK-293T (Lane 2). The antibody was developed with Goat Anti-Rabbit IgG, Peroxidase conjugate (Cat. No. A0545) and a chemiluminescent substrate. Antibody dilution: 1.5 μg/mL.
Immunoblotting Cell and tissue lysates were separated on SDS-PAGE, blotted with 1.5 μg/mL Anti-ATP13A2 (C-terminal region) (Cat. No. A3361) and developed using Goat Anti-Rabbit IgG-Peroxidase (Cat. No. A0545) and chemiluminescent substrate. Lanes 1. Mouse brain (cytosolic S1 fraction) 2. HEK-293T overexpressing human ATP13A2 3. HEK-293T untransfected 4. Mouse brain (cytosolic S1 fraction). Antibody + ATP13A2 immunizing peptide (human, 804-821)
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| concentration | ~1.5 mg/mL |
| conjugate | unconjugated |
| enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation  |
| form | buffered aqueous solution |
| mol wt | antigen ~129 kDa |
| Quality Level | 200 |
| shipped in | dry ice |
| species reactivity | mouse, human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | western blot: 1.5-3.0 μg/mL using mouse brain extract (S1 fraction) or HEK-293T cells expressing human ATP13A2 |
| UniProt accession no. | Q9NQ11  |
| Application: | Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Western Blotting (1 paper) |
| Application: | Rabbit anti-ATP13A2 (C-terminal region) antibody has been used for western blotting applications at a dilution of 1:1000. |
| Biochem/physiol Actions: | ATP13A2 (ATPase type 13A2, also known as PARK9) shows elevated expression levels in the brains of sporadic Parkinson′s disease (PD) patients, suggesting a potential role in the more common forms of PD. It is associated with Kufor-Rakeb syndrome (KRS). KRS is a rare form of hereditary PD with juvenile onset. In addition to typical signs of PD, affected individuals show symptoms of more widespread pyramidal neurodegeneration, including dementia. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | ATP13A2 (ATPase type 13A2, also known as PARK9) is a neuronal P-type ATPase of the P5 subfamily. It is present in the lysosome of transiently transfected cells, whereas the unstable truncated mutants are retained in the endoplasmic reticulum and degraded by the proteasome. |
| General description: | ATP13A2 is a member of the P5 subfamily of P-type transport ATPases which include ATP13A1-ATP13A5. Mutations in ATP3A2 also known as PARK9 are associated with hereditary Parkinson′s disease. |
| General description: | Rabbit anti-ATP13A2 (C-terminal region) antibody is specific for human and mouse ATP13A2. Staining of the ATP13A2 band by immunoblotting is specifically inhibited by the ATP13A2 immunizing peptide. |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| WGK Germany | nwg |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |